Effect of atorvastatin on tumor growth and metastasis
in a breast cancer cell xenograft model and its mechanism
Effect of atorvastatin on tumor growth and metastasis
in a breast cancer cell xenograft model and its mechanism
Liu LIU MD, PhD1,Yaogui NING MM2,Chen CHEN MD2,Daowen WANG MD, PhD2,
1.Department of Nephrology,
Tongji Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan 430030, China; 2.Department of Cardiology,
Tongji Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan 430030, China;
Abstract：This paper aims to evaluate the effects and the possible mechanisms of atorvastatin on tumor growth and metastasis in a xenograft tumor model. Twenty-four female athymic BALB/C mice with MDA-MB-435 xenograft tumors were randomly assigned to three groups: a control group, a low-dose atorvastatin treatment group, and a high-dose atorvastatin treatment group. The mice in the treatment groups began to be administered with atorvastatin (10 or 20 mg/kg per day) when the xenograft tumors reached 1 cm in diameter. At the end of the experiment, the tumor volume and weight and the lung metastasis colonies of each mouse were measured. Western blotting was applied to detect phosphorylation of protein kinase B (PKB, Akt), extracellular signal regulated kinase (ERK), c-Jun N-terminal Kinase (JNK), and the expression of cytochrome P450 (CYP) subtype CYP2J2. Atorvastatin suppressed xenograft tumor growth and metastasis both in the low-dose and the high-dose treatment groups (P < 0.05). Atorvastatin also decreased the phosphorylated Akt (p-Akt) and p-ERK but increased p-JNK expression. However, atorvastatin did not alter the expression of CYP2J2 in tumor tissue. This suggests that atorvastatin has the efficacy of suppressing tumor growth and metastasis in vivo. These effects were not dependent on down-regulation of CYP2J2 expression.
. Effect of atorvastatin on tumor growth and metastasis
in a breast cancer cell xenograft model and its mechanism[J]. Front. Med., 2009, 3(4): 443-446.
Liu LIU MD, PhD, Yaogui NING MM, Chen CHEN MD, Daowen WANG MD, PhD, . Effect of atorvastatin on tumor growth and metastasis
in a breast cancer cell xenograft model and its mechanism. Front. Med., 2009, 3(4): 443-446.
Harris R E, Alshafie G A, Abou-Issa H, Seibert K. Chemopreventionof breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res, 2000, 60(8): 2101―2103
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M J. Cancer statistics, 2003. CACancer J Clin, 2003, 53(1): 5―26 doi: 10.3322/canjclin.53.1.5
Athyros V G, Kakafika A I, Tziomalos K, Karagiannis A, Mikhailidis D P. Pleiotropic effects of statins–clinicalevidence. Curr Pharm Des, 2009, 15(5): 479―489 doi: 10.2174/138161209787315729
Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: A systematicreview and meta-analysis. Eur J Cancer, 2008, 44(15): 2122―2132 doi: 10.1016/j.ejca.2008.06.025
Jiang J G, Chen C L, Card J W, Yang S, Chen J X, Fu X N, Ning Y G, Xiao X, Zeldin D C, Wang D W. Cytochrome P450 2J2 promotesthe neoplastic phenotype of carcinoma cells and is up-regulated inhuman tumors. Cancer Res, 2005, 65(11): 4707―4715 doi: 10.1158/0008-5472.CAN-04-4173
Jiang J G, Ning Y G, Chen C, Ma D, Liu Z J, Yang S, Zhou J, Xiao X, Zhang X A, Edin M L, Card J W, Wang J, Zeldin D C, Wang D W. Cytochromep450 epoxygenase promotes human cancer metastasis. Cancer Res, 2007, 67(14): 6665―6674 doi: 10.1158/0008-5472.CAN-06-3643
Liao J K. Effects of statins on 3-Hydroxy-3-methyglutaryl coenzyme A reductaseinhibition beyond low-density lipoprotein cholesterol. Am J Cardiol, 2005, 96[5A]: 24F―33F doi: 10.1016/j.amjcard.2005.06.009
Adam O, Neuberger H R, Böhm M, Laufs U. Preventionof atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme Areductase inhibitors. Circulation, 2008, 118(12): 1285―1293 doi: 10.1161/CIRCULATIONAHA.107.760892
Sahai E, Marshall C J. Rho-GTPases and cancer. Nat Rev Cancer, 2002, 2(2): 133―142 doi: 10.1038/nrc725
Garwood E R, Kumar A S, Baehner F L, Moore D H, Au A, Hylton N, Flowers C I, Garber J, Lesnikoski B A, Hwang E S, Olopade O, Port E R, Campbell M, Esserman L J. Fluvastatin reduces proliferation and increases apoptosis in womenwith high grade breast cancer. Breast CancerRes Treat, 2009Aug29. [Epub ahead of print]
Kang S, Kim E S, Moon A. Simvastatin and lovastatin inhibit breast cell invasioninduced by H-Ras. Oncol Rep, 2009, 21(5): 1317―1322
Mannello F, Tonti G A. Statins and breast cancer:may matrix metalloproteinase be the missing link. Cancer Invest, 2009, 27(4): 466―470 doi: 10.1080/07357900802491444
Sánchez C A, Rodríguez E, Varela E, Zapata E, Páez A, Massó F A, Montaño L F, Lóopez-Marure R. Statin-inducedinhibition of MCF-7 breast cancer cell proliferation is related tocell cycle arrest and apoptotic and necrotic cell death mediated byan enhanced oxidative stress. Cancer Invest, 2008, 26(7): 698―707 doi: 10.1080/07357900701874658
Herrero-Martin G, López-Rivas A. Statins activatea mitochondria-operated pathway of apoptosis in breast tumor cellsby a mechanism regulated by ErbB2 and dependent on the prenylationof proteins. FEBS Lett, 2008, 582(17): 2589―2594 doi: 10.1016/j.febslet.2008.06.034
Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K. HMG-CoA reductase expression in breast cancer is associatedwith a less aggressive phenotype and influenced by anthropometricfactors. Int J Cancer, 2008, 123(5): 1146―1153 doi: 10.1002/ijc.23597
Campbell M J, Esserman L J, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar A S, Adduci K, Marx C, Petricoin E F, Liotta L A, Winters M, Benz S, Benz C C. Breast cancer growth prevention by statins. Cancer Res, 2006, 66(17): 8707―8714 doi: 10.1158/0008-5472.CAN-05-4061
Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancercells: p53 and estrogen receptor independent pathway requiring signalingthrough JNK. Cancer Lett, 2007, 250(2): 220―228 doi: 10.1016/j.canlet.2006.10.009
Denoyelle C, Albanese P, Uzan G, Hong L, Vannier J P, Soria J, Soria C. Molecular mechanism of theanti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase,on aggressive human breast cancer cells. Cell Signal, 2003, 15(3): 327―338 doi: 10.1016/S0898-6568(02)00124-9
Zeldin D C. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem, 2001, 276(39): 36059―36062 doi: 10.1074/jbc.R100030200
